

David Cornlath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8503277/publications.pdf>

Version: 2024-02-01

75
papers

7,064
citations

117625
34
h-index

82547
72
g-index

78
all docs

78
docs citations

78
times ranked

4153
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2022, 145, 887-896.	7.6	16
2	Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. <i>Clinical Neurophysiology</i> , 2022, 138, 231-240.	1.5	7
3	Analysis of relapse by inflammatory Rasch-built overall disability scale status in the <sc>PATH</sc> study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 159-165.	3.1	3
4	COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations. <i>Brain</i> , 2021, 144, 357-360.	7.6	77
5	A recurrent <i>MORC2</i> mutation causes Charcot-Marie-Tooth disease type 2Z. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 184-186.	3.1	3
6	Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 275-283.	10.2	34
7	Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1080-1088.	1.9	6
8	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>Journal of the Peripheral Nervous System</i> , 2021, 26, 242-268.	3.1	176
9	European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. <i>European Journal of Neurology</i> , 2021, 28, 3556-3583.	3.3	153
10	Maybe myopathic EMG but not myopathy. <i>Clinical Neurophysiology</i> , 2021, 132, 2323.	1.5	1
11	Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 113-121.	1.9	34
12	Fatigue in chronic inflammatory demyelinating polyradiculoneuropathy. <i>Muscle and Nerve</i> , 2020, 62, 649-651.	2.2	3
13	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The <sc>PATH</sc> study and a systematic review. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 230-237.	3.1	15
14	A novel HSPB1 mutation associated with a late onset CMT2 phenotype: Case presentation and systematic review of the literature. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 223-229.	3.1	5
15	Subacute sensory neuronopathy and cancer: the identification of paraneoplastic syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 793-794.	1.9	1
16	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	1.9	43
17	Yield of next-generation neuropathy gene panels in axonal neuropathies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 324-329.	3.1	7
18	Chemotherapy-induced peripheral neurotoxicity: Facts, needs and future directions. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S86-S87.	3.1	1

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e590.	6.0	37
20	Diagnosis and management of Guillain-Barré syndrome in ten steps. <i>Nature Reviews Neurology</i> , 2019, 15, 671-683.	10.1	463
21	Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 48-55.	3.1	17
22	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 72-79.	3.1	13
23	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	3.1	20
24	Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. <i>Lancet Neurology</i> , The, 2019, 18, 784-794.	10.2	136
25	Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity. <i>Current Opinion in Neurology</i> , 2019, 32, 676-683.	3.6	17
26	A randomised, multicentre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 108-114.	3.1	14
27	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2018, 17, 35-46.	10.2	193
28	046...Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A19.2-A19.	1.9	0
29	Regional variation of Guillain-Barré syndrome. <i>Brain</i> , 2018, 141, 2866-2877.	7.6	190
30	Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-CBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial. <i>Journal of the Peripheral Nervous System</i> , 2018, 23, 210-215.	3.1	36
31	IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. <i>Immunotherapy</i> , 2018, 10, 919-933.	2.0	10
32	Differentiating lower motor neuron syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 474-483.	1.9	93
33	International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 68-76.	3.1	89
34	Pain in chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2017, 22, 156-161.	3.1	26
35	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 345.	1.6	21
36	Does ability to walk reflect general functionality in inflammatory neuropathies?. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 74-81.	3.1	13

#	ARTICLE	IF	CITATIONS
37	Comparing the <scp>NIS</scp> vs. <scp>MRC</scp> and <scp>INCAT</scp> sensory scale through Rasch analyses. Journal of the Peripheral Nervous System, 2015, 20, 277-288.	3.1	27
38	Raschâ€transformed Total Neuropathy Score clinical version (RTâ€TNS^{Â©}) in patients with chemotherapyâ€induced peripheral neuropathy. Journal of the Peripheral Nervous System, 2015, 20, 328-332.	3.1	24
39	Grip strength comparison in immuneâ€mediated neuropathies: Vigorimeter vs. Jamar. Journal of the Peripheral Nervous System, 2015, 20, 269-276.	3.1	28
40	Impairment measures versus inflammatory <scp>RODS</scp> in <scp>GBS</scp> and <scp>CIDP</scp>: a responsiveness comparison. Journal of the Peripheral Nervous System, 2015, 20, 289-295.	3.1	30
41	Raschâ€built Overall Disability Scale for Multifocal motor neuropathy (<scp>MMNâ€RODS</scp>^{Â©}). Journal of the Peripheral Nervous System, 2015, 20, 296-305.	3.1	38
42	Changing outcome in inflammatory neuropathies. Neurology, 2014, 83, 2124-2132.	1.1	89
43	The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical Trials. Clinical Therapeutics, 2012, 34, 1056-1069.	2.5	29
44	Report from the Satellite Meeting of the Peripheral Nerve Society in Sydney, Australia, July 5-7, 2010. Journal of the Peripheral Nervous System, 2010, 15, 161-163.	3.1	0
45	Letter from new Editor-in-Chief. Journal of the Peripheral Nervous System, 2007, 12, 1-1.	3.1	1
46	Recent advances in HIV neuropathy. Current Opinion in Neurology, 2006, 19, 446-450.	3.6	61
47	Electrophysiological studies in the Guillain-Barrÿ½ syndrome: Distinguishing subtypes by published criteria. , 1998, 21, 1275-1279.		79
48	Electrophysiological studies in the Guillainâ€Barrÿ© syndrome: Distinguishing subtypes by published criteria. Muscle and Nerve, 1998, 21, 1275-1279.	2.2	1
49	Sensory nerve pathology in multifocal motor neuropathy. Annals of Neurology, 1996, 39, 319-325.	5.3	89
50	Vestibular dysfunction in chronic inflammatory demyelinating Polyneuropathy. Annals of Neurology, 1996, 39, 529-535.	5.3	32
51	Multifocal motor neuropathy: Electrodiagnostic features. Muscle and Nerve, 1994, 17, 198-205.	2.2	126
52	Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Annals of Neurology, 1994, 35, 304-311.	5.3	334
53	The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Annals of Neurology, 1994, 36, 244-246.	5.3	382
54	Multifocal motor neuropathy: Response to human immune globulin. Annals of Neurology, 1993, 33, 237-242.	5.3	193

#	ARTICLE	IF	CITATIONS
55	Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. <i>Nature Genetics</i> , 1992, 2, 148-152.	21.4	140
56	Wallerian degeneration in human nerves: Serial electrophysiological studies. <i>Muscle and Nerve</i> , 1992, 15, 687-693.	2.2	207
57	Nerve conduction studies in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 1992, 15, 1111-1115.	2.2	97
58	Werdnig-Hoffmann disease and chronic distal spinal muscular atrophy with apparent autosomal dominant inheritance. <i>Annals of Neurology</i> , 1992, 32, 404-407.	5.3	9
59	Conduction block in diabetic neuropathy. <i>Muscle and Nerve</i> , 1991, 14, 858-862.	2.2	43
60	Stimulated single-fiber electromyography in lambert-eaton myasthenic syndrome. <i>Muscle and Nerve</i> , 1991, 14, 1227-1230.	2.2	25
61	Excitatory amino acids in amyotrophic lateral sclerosis: An update. <i>Annals of Neurology</i> , 1991, 30, 224-225.	5.3	95
62	Inter- and intra-examiner reliability of nerve conduction measurements in normal subjects. <i>Annals of Neurology</i> , 1991, 30, 841-843.	5.3	101
63	Assessment of current diagnostic criteria for Guillain-Barré syndrome. <i>Annals of Neurology</i> , 1990, 27, S21-S24.	5.3	1,731
64	Macrophage responses in inflammatory demyelinating neuropathies. <i>Annals of Neurology</i> , 1990, 27, S64-S68.	5.3	76
65	Paramyotonia congenita or hyperkalemic periodic paralysis? Clinical and electrophysiological features of each entity in one family. <i>Muscle and Nerve</i> , 1990, 13, 21-26.	2.2	55
66	Spontaneous diabetes mellitus in a rhesus monkey: Neurophysiological studies. <i>Muscle and Nerve</i> , 1989, 12, 233-235.	2.2	15
67	Electrodiagnosis of human colchicine myoneuropathy. <i>Muscle and Nerve</i> , 1989, 12, 360-364.	2.2	38
68	Motor conduction studies in guillain-barré syndrome: Description and prognostic value. <i>Annals of Neurology</i> , 1988, 23, 354-359.	5.3	171
69	Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings. <i>Annals of Neurology</i> , 1988, 23, S34-S37.	5.3	156
70	Treatment of the neuromuscular complications of human immunodeficiency virus infection. <i>Annals of Neurology</i> , 1988, 23, S88-S91.	5.3	53
71	Assessment of thoracic paraspinal muscles in the diagnosis of ALS. <i>Muscle and Nerve</i> , 1988, 11, 484-492.	2.2	102
72	Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. <i>Annals of Neurology</i> , 1987, 21, 32-40.	5.3	373

#	ARTICLE	IF	CITATIONS
73	Immunoreactive myelin basic protein in cerebrospinal fluid of patients with peripheral neuropathies. Annals of Neurology, 1986, 20, 370-372.	5.3	8
74	Disorders of neuromuscular transmission in infants and children. Muscle and Nerve, 1986, 9, 606-611.	2.2	25
75	Diagnosis and management of Guillain-Barré syndrome in ten steps. , 0, .		1